Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma 16-10-2023, 19:21

Fortrea Completes Expansion of Clinical Pharmacology Solutions Following Targeted Investments at its Four Clinical Research Units in U.S. and U.K. 2-11-2023, 18:00

Meltwater Winter Product Release delivers greater impact with faster time to value, better analytics and continuous rollout of generative AI capabilities 19-10-2023, 22:00